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Dear Editor, 
We have read the article of Arola and colleagues [1] with 
great interest. The authors report a candidate gene 
approach in the MYOZ1 gene encoding calsarcin-2 in 185 
patients with idiopathic dilated cardiomyopathy (iDCM). 
No disease associated mutation was identified by use of 
denaturing high-performance liquid chromatography 
(DHPLC). 
We have examined a cohort of 61 patients with proven 
familial dilated cardiomyopathy (fDCM). fDCM was 
diagnosed when two or more affected relatives were 
present in one family (range: 2–7; mean: 3.2). Clinical 
examination was performed according to the European 
guidelines for investigation of familial dilated 
cardiomyopathy [2] as described previously [3]. We 
directly sequenced all coding exons (2–6) with flanking 
intronic portions of MYOZ1 by use of ABI Big Dye 
chemistry as described in detail in [4]. In contrast to Arola 
et al. [1], we additionally analyzed exonic fragments (2–6) 
of MYOZ2 encoding the cardiac calsarcin-1. 
We also identified the L255L (CTG > CTT) variant as 
described in [1]. Five fDCM patients were heterozygous 
L255L carriers. However, no other genetic variant in 
MYOZ1 could be detected by us. Sequencing of MYOZ2 
resulted in identification of two synonymous 
polymorphisms (A79A and E153E). These heterozygous 
variants were uniquely detected in two individuals with 
fDCM. All identified polymorphisms in MYOZ1 and 
MYOZ2 are represented in Fig. 1. 
Although DHPLC has been proven to be a sensitive 
method for mutational analysis, one can not completely 
exclude that some variants might have escaped the 
analysis of Arola and colleagues. However, direct 
sequencing constitutes the gold standard of genetic 
analysis almost excluding false negative results in 
candidate gene approaches. Furthermore, screening in 
patients with a hereditary form of DCM offers several 
advantages: first, the prevalence of pathogenic mutations 
should be higher in patients with familial DCM. Further, 
identified unknown variants can easily be checked for co-
segregation with the disease in the family pedigrees. 
Secondly, in case of negative results (as described here) 
the probability that the respective candidate gene does 
not constitute a relevant disease gene is higher when 
screening a cohort with familial disease. 
The most important point to address to the work 
described by Arola et al. [1] is that the analysis should not 
be restricted to MYOZ1 when investigating the genetic 
etiology of DCM. Indeed, MYOZ1 is abundantly 
expressed in skeletal muscle, but cardiomyocytes reveal 
a very weak mRNA expression of MYOZ1 [5]. Conversely, 
MYOZ2 encoding calsarcin-1 is predominantly expressed 
in cardiomyocytes and to lesser extends in skeletal 
muscle [5,6]. Calsarcin-1 is located at the sarcomeric Z-
disk and interacts with DCM disease genes like telethonin 
and a-actinin. Furthermore, conditional MYOZ2 knock out 
mice reveal heart failure and extensive dilation of both 
ventricles after aortic banding [7]. Therefore, MYOZ2 
represents a more plausible candidate gene for DCM. 
However, taking together the results from Arola et al. [1] 
with results from a recent candidate gene approach 
analyzing MYOZ2 [8], pathogenic mutations in MYOZ1 
and MYOZ2 could not be identified in 185 and 19 patients 
with idiopathic DCM patients, respectively. Additionally, 
we have excluded mutations in both genes in a cohort of 
61 carefully selected families with fDCM using a highly 
sensitive screening method. 
In conclusion, one can state that mutations in MYOZ1 and 
MYOZ2 are at least very rare events as an underlying 
disease mechanism for idiopathic or familial DCM. 
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Fig.1: Schematic representation of the gene structure of MYOZ1 
(NM_021245) encoding calsarcin-2 and MYOZ2 (NM_016599) 
encoding calsarcin-1 with the variants identified by Arola et al. [1] 
and us indicated. Open boxes represent exons with the number of 
coding nucleotides above and UTRs shaded. The S50S variant in 
MYOZ1 was described by Arola et al. [1], whereas the L255L 
variant in MYOZ1 was identified by Arola et al. and us (allelic 
frequency 8.2%). The A79A and E153E polymorphisms in MYOZ2 
were identified in two patients of our fDCM cohort, respectively. 
Many different and overlapping protein–protein interaction domains 
have been described for calsarcin-1 and calsarcin-2 in different 
studies [5] and [6]. 
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